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Abstract 
Background: MicroRNAs (miRNAs) play key roles in cancer development and progression. The purpose of the pre-
sent study was to determine the expression levels of miR-133a and miR-539 in osteosarcoma patients and to further 
investigate the clinicopathological, and prognostic value of these miRNAs.
Methods: The expression levels of miR-133a and miR-539 were determined by qRT-PCR. Associations between 
miRNAs expressions and various clinicopathological characteristics were analyzed. Survival rate was determined with 
Kaplan–Meier and statistically analyzed with the log-rank method between groups. Survival data were evaluated 
through multivariate Cox regression analysis
Results: Our findings revealed that the miR-133a expression was significantly decreased in clinical osteosarcoma 
tissues compared to adjacent normal bone tissues. The expression level of miR-539 was decreased in clinical osteo-
sarcoma tissues as compared to those adjacent normal tissues. Low expressions of miR-133a and miR-539 were 
significantly association with advanced TNM stage (P = 0.002; P = 0.001), and metastasis or recurrence (P = 0.001; 
P = 0.01). Furthermore, Kaplan–Meier survival analysis and log-rank test showed that the low expressions of miR-133a 
and miR-539 were correlated with the reduced overall survival of osteosarcoma patients. Multivariate Cox propor-
tional hazards model showed that decreased expressions of miR-133a and miR-539 (P = 0.007; P = 0.02), TNM stage 
(P = 0.001; P = 0.002), and metastasis or recurrence (P = 0.005; P = 0.026) were independent prognostic markers of 
overall survival of patients.
Conclusion: These results suggest that decreased miR-133a and miR-539 expressions may participate in the progres-
sion of osteosarcoma. Together, these results showed that miR-133a and miR-539 may have their role in both progres-
sion and prognosis of osteosarcoma.
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Background
One of the most common primary bone tumors in chil-
dren and adolescents is osteosarcoma, which is most 
often localized in the metaphysis of the adolescent long 
bones [1]. More than 50  % of patients who are chem-
oresistant have an extremely poor prognosis due to 
lung metastasis [2]. The 5-year overall and disease-free 
survival rates for osteosarcoma patients are around 
50–60  % [3]. Despite the advances in therapeutic strat-
egies, there is dissatisfactory for most osteosarcoma 
patients with metastasis or recurrence. Therefore, it is 
required to identify biomarkers, and therapeutic targets 
for osteosarcoma.
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MicroRNAs (miRNAs) are endogenous 19e25 nt non-
coding RNAs that can bind the 3′-untranslated region 
(3′-UTR) of specific genes to inhibit the translation of 
corresponding mRNA targets. Increasing evidence dem-
onstrates that the deregulations of miRNAs are involved 
in various biological processes including proliferation, 
differentiation, and apoptosis [4]. Current evidences indi-
cate that miRNAs have their role in tumorigenesis and 
provide new insights into the molecular mechanisms 
underlying carcinogenesis. Different miRNAs have been 
shown to participate in the initiation and progression of 
osteosarcoma [5–8]. Recently, it has been reported that 
miR-539 may inhibit cell proliferation through suppress-
ing the MITF expression [9]. MiR-539 were confirmed 
to be down-regulated in osteosarcoma cell lines [10, 11]. 
MiR-133a is also shown to be an important regulator in 
osteogenesis, and its down-regulation has been reported 
in bone morphogenetic protein (BMP)-induced osteogen-
esis. Moreover, it can function as suppressor of RunX2 
expression for inhibition of osteoblast differentiation [12]. 
Further investigations are required to identify miR-133a 
and miR-539 expression levels in clinical osteosarcoma 
patients and its potential roles in osteosarcoma carcino-
genesis and progression. Therefore, we examined the clin-
ical importance of miR-133a and miR-539 expressions in 
osteosarcoma tissue samples using real-time PCR.
Methods
Patients
The samples of cancer tissue and corresponding non-
cancerous bone tissues were collected between 2010 and 
2014 from 35 patients who were undergoing surgery in 
different hospitals of Tehran, Iran. None of the patients 
received radiotherapy and chemotherapy before the tis-
sues were collected. Informed consents were obtained 
from all the patients. All specimens were obtained during 
surgery, frozen immediately in liquid nitrogen, and were 
stored at -80 °C. Furthermore, the diagnosis and the his-
tological grading were proved by pathologists. The clin-
icopathological features are summarized in Tables 1 and 
2. 
Real‑time quantitative PCR
Total RNA was extracted using miRNeasy kit (Qia-
gen) according to the manufacturer’s instructions. The 
expression levels of miRNAs quantitated using the 
TaqMan miRNA assey kit (Applied Biosystems). Real-
timePCR was performed using Rotor Gene 6000 Real-
Time PCR (Qiagen, Germany) with an invitrogen kit 
and a TaqMan universal PCR master mix. The relative 
expression levels of miRNAs were normalized to that 
of internal control U6 by using 2−Ct cycle threshold 
method [13].
Statistical analysis
Our data were evaluated using SPSS 19.0 software (SPSS 
Inc., USA). The differences between two groups were 
analyzed using the Student’s t-test. The statistical analysis 
of cases in groups were performed using the Chi square 
test. Moreover, log-rank test and Kaplan–Meier method 
were used to evaluate survival rate in patients with osteo-
sarcoma. Multivariate analysis was performed to evaluate 
prognostic values using Cox proportional hazards model. 
P  <  0.05 was used to indicate a statistically significant 
difference.
Results
As demonstrated by quantitative real-time PCR, the 
miR-133a expression was significantly decreased in 
clinical osteosarcoma tissues (median relative expres-
sion level ± SD: 3.74 ± 1.83) compared to adjacent nor-
mal bone tissues (median relative expression level ± SD: 
15.23 ± 3.25, P < 0.001; Fig. 1).
The expression level of miR-539 was decreased in 
clinical osteosarcoma tissues (median relative expres-
sion level ± SD: 2.23 ± 1.02) as compared to that adja-
cent normal tissues (mean ± SD: 5.68 ± 1.42, P < 0.0001; 
Fig. 2).
Correlation of miRNAs expressions with the 
clinicopathological fetures
The patients with osteosarcoma were classified into two 
groups based on the median expression levels.
Low expression of miR-133a showed significant asso-
ciation with advanced TNM stage (P  =  0.002), and 
metastasis or recurrence (P = 0.001). But no significant 
association with other clinical factors (Table  1). On the 
other hand, low expression of miR-539 were significantly 
correlated with advanced TNM stage (P  =  0.001), and 
metastasis or recurrence (P  =  0.01). But no significant 
association with other clinical factors (Table 2). Further-
more, Kaplan–Meier survival analysis and log-rank test 
showed that the low expressions of miR-133a and miR-
539 were correlated with the reduced overall survival of 
osteosarcoma patients (log-rank test P  <  0.001; Figs.  3, 
4). Multivariate Cox proportional hazards model showed 
that decreased expressions of miR-133a and miR-539 
(P = 0.007; P = 0.02), TNM stage (P = 0.001; P = 0.002), 
and metastasis or recurrence (P = 0.005; P = 0.026) were 
independent prognostic markers of overall survival of 
patients (Tables 3, 4).
Discussion
Various deregulated miRNAs, have been reported in 
osteosarcoma development [14]. Nevertheless, it is still 
an ongoing process to elucidate new important deregu-
lated miRNAs and their roles in cancer carcinogenesis 
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and progression. In the present study, we found that the 
miR-133a was significantly decreased in clinical osteosar-
coma tissues compared to adjacent normal bone. More-
over, low expression of miR-133a showed significant 
Table 1 The association between  miR-133a expression 
and  characteristics of  patients suffering from  osteosar-
coma
Clinicopathological 
features
No. of  
cases
Expression  
of miR‑133a
P value of  
miR‑133a
Low, 19 High, 16
Gender
 Male 18 6 12 NS
 Female 17 13 4
Age
 ≤40 20 9 11 NS
 >40 15 10 5
Tumor diameter (cm)
 ≤5 21 10 11 NS
 >5 14 9 5
Differentiation
 Well and moderate 16 7 9 NS
 Poor 19 12 7
TNM stage
 I + II 15 5 10 0.002
 III + IV 20 14 6
Metastasis or recurrence
 Yes 19 16 3 0.001
 No 16 3 13
Table 2 The association between  miR-539 expression 
and  characteristics of  patients suffering from  osteosar-
coma
Clinicopathological 
features
No. of  
cases, 35
Expression of  
miR‑539
P value
Low, 21 High, 14
Gender
 Male 15 9 6 NS
 Female 20 12 8
Age
 ≤40 19 10 9 NS
 >40 16 11 5
Tumor diameter (cm)
 ≤5 21 11 10 NS
 >5 14 10 4
Differentiation
 Well and moderate 18 9 9 NS
 Poor 17 12 5
TNM stage
 I + II 12 5 7 0.001
 III + IV 23 16 7
Metastasis or recurrence
 Yes 22 16 6 0.01
 No 13 5 8
Fig. 1 The relative expression level of miR-133a between osteosar-
coma bone tissue and noncancerous bone tissues
Fig. 2 The relative expression level of miR-539 between osteosar-
coma bone tissue and noncancerous bone tissues
Fig. 3 Correlation between miR-133a expression and survival in 
patients
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association with advanced TNM stage, and metastasis or 
recurrence. Kaplan–Meier survival analysis and log-rank 
test showed that the low expression of miR-133a was cor-
related with the reduced overall survival of osteosarcoma 
patients. Multivariate Cox proportional hazards model 
showed that decreased expressions of miR-133a, TNM 
stage, and metastasis were independent prognostic mark-
ers of overall survival of patients. Recently, miR-133a is 
also reported to be an important regulator in osteogen-
esis, and miR-133a expression was proved to play an 
important role during osteoblast differentiation, by the 
finding that BMP2 treatment could decrease the expres-
sion of miR-133a during osteoblast lineage commitment 
and osteogenesis [12]. Ji et  al. [15] reported that miR-
133a expression was significantly suppressed in tumor 
tissues as compared to that in adjacent normal tissues. 
They found that miR-133a expression in tumor tissues 
was significantly reverse-correlated with osteosarcoma 
clinical tumor and Kaplan–Meier survival analysis also 
revealed that low miR-133a expression in tumor tissues 
was significantly correlated with the reduced overall sur-
vival of osteosarcoma patients.
They indicated that miR-133a might function as a 
tumor suppressor or an antionco-miRNA in cancer car-
cinogenesis and progression. Previous reports revealed 
the roles of miR-133a in some other kinds of cancer, such 
as prostate cancer, bladder cancer, and esophagus cancer 
[16–18]. Among them, miR-133a expression is down-
regulated in all these types of cancer, but the underlying 
mechanisms which mediate the down-regulation of miR-
133a in cancer required to further investigations.
Previous studies reported that the expression of Bcl-xL, 
is also associated with overall survival of osteosarcoma 
patients [19]. These results indicated that miR-133a may 
be effective to predict the prognosis of osteosarcoma 
patients. Human important anti-apoptotic molecules 
Bcl-xL and Mcl-1 are determined to be new direct tar-
gets of miR-133a in osteosarcoma, indicating that miR-
133a may exert its pro-apoptotic function throughout 
inhibiting Bcl-xL and Mcl-1 expression. Human EGFR, 
TAGLN2, and FSCN1 reported to be molecular targets of 
miR-133a in other kinds of cancers [16–18]. The recent 
evidence indicated that cancer pathways may be regu-
lated by miR-133a expression, and miR-133a may be a 
new therapeutic target to repress cancer progression.
In the present study, the expression level of miR-539 
was decreased in clinical osteosarcoma tissues as com-
pared to those adjacent normal tissues. Furthermore, 
low expression of miR-539 was significantly correlated 
with advanced TNM stage, and metastasis or recurrence. 
Kaplan–Meier survival analysis and log-rank test showed 
that the low expression of miR-539 was correlated with 
the reduced overall survival of osteosarcoma patients. 
Multivariate Cox proportional hazards model showed 
that decreased expressions of miR-539, TNM stage, and 
metastasis or recurrence were independent prognostic 
markers of overall survival of patients. Recently, it has 
been reported that miR-539 may inhibit cell proliferation 
through suppressing the MITF expression [9]. Moreover, 
miR-539 were confirmed to be down-regulated in osteo-
sarcoma cell lines [10, 11].
Fig. 4 Correlation between miR-539 expression and survival in 
patients
Table 3 Multivariate analysis of the correlation of progno-
sis miR-133a with clinicopathological factors
Clinicopathological characteristics HR 95 % CI P value
Gender 1.264 0.624–1.612 0.521
Age 1.365 0.725–1.937 0.4
TNM stage 3.618 1.319–10.261 0.001
Tumor diameter (cm) 0.89 0.615–1.523 0.2
Metastasis or recurrence 3.28 3.278–9.972 0.005
Differentiation 1.015 0.693–1.371 0.31
miR-133a expression 3.421 1.326–9.371 0.007
Table 4 Multivariate analysis of the correlation of progno-
sis miR-539 with clinicopathological factors
Clinicopathological characteristics HR 95 % CI P value
Gender 1.03 0.532–1.762 0.541
Age 0.73 0.382–1.108 0.527
TNM stage 4.96 2.462–11.72 0.002
Tumor diameter (cm) 1.21 0.73–2.03 0.374
Metastasis or recurrence 3.77 1.538–8.725 0.026
Differentiation 1.316 1.035–2.441 0.3
miR-539 expression 3.68 2.153–10.227 0.02
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There are few studies that have described the function 
of miR-539. One study indicated that miR-539 is among 
the factors sensing cellular biotin levels and targets 
holocarboxylase synthetase (HCS) [12]. Another study, 
showed that miR-539 suppress O-GlcNAcase expres-
sion and play an important role in the failing heart [20]. 
Moreover, it has been reported that miR-539 participates 
in the regulation of mitochondrial activity and apoptosis 
through targeting PHB2 [21].
The expression of miR-539 was previously analyzed 
in human thyroid cancer cell lines and in normal thy-
roids (NT). It has revealed that miR-539 expression was 
decreased compared to normal control [22]. Further-
more, it has been found that miR-539 plays a suppres-
sor role in thyroid cancer cell migration and invasion 
and miR-539 binding to the 3′-UTR region of CARMA1 
inhibited the expression of CARMA1 in thyroid cancer 
cells. Mentioned study indicated that miR-539 is a novel 
regulator of migration and invasion in human thyroid 
cancer cells by targeting CARMA1 [22]. However, further 
studies are needed to verify the role miR-539 in develop-
ing of different cancer types.
Conclusion
In conclusion, these results suggest that decreased miR-
133a and miR-539 expressions may participate in the pro-
gression of osteosarcoma. Together, these results showed 
that miR-133a and miR-539 may have their role in both pro-
gression and prognosis of osteosarcoma. However, further 
studies are required to identify the role of these miRNAs in 
progression and prognosis of osteosarcoma by their targets.
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